Peetz Christopher sold $2.0M of MIRM
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 20,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $98.92 ($98.51–$100.14, $1.98M total) across 3 trades on 2026-08-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan; no new company fundamentals are provided.
Market read
Traders may monitor insider selling as a sentiment input, but this specific disclosure lacks a fundamental catalyst.
What to watch
The filing does not reveal whether the CEO’s remaining holdings are increasing via other grants or purchases, so sentiment should be weighed against the broader insider activity trend.
Background
The article is a SEC Form 4 insider transaction report for Mirum Pharmaceuticals, Inc., filed by CEO Peetz Christopher.
Ticker impact
CEO Peetz Christopher sold about 20,000 shares in open-market transactions at $98.51 to $100.14, totaling ~$1.98M, under a 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around insider selling.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and it provides no new operational, financial, or regulatory information about Mirum Pharmaceuticals.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated; this is a US-listed issuer insider transaction.
None indicated; no cross-border deal, trial, or regulatory action is described.
Counterpoint
Insider sales can be interpreted as liquidity-driven rather than bearish, especially when executed under a 10b5-1 plan.
Key entities
- issuerMirum Pharmaceuticals, Inc.
US-listed company whose CEO executed open-market sales disclosed on Form 4.
- insiderPeetz Christopher
Chief Executive Officer and director who sold shares under a 10b5-1 plan.
